A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting

Cesur, Mustafa; Çorapçıoğlu, Demet; Gürsoy, Alptekin; Gonen, Mustafa Sait; Ozduman, Mine; Emral, Rıfat; Uysal, Ali Rıza; Tonyukuk, Vedia; Yilmaz, Arif Ender; Bayram, Fahri; Kamel, Nurí

doi:10.1016/j.diabres.2006.05.012

Cited by 70 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In two small observational studies, no hypoglycaemic events were reported in patients treated with repaglinide during Ramadan [26,27]. A third study demonstrated no difference in hypoglycaemia when compared with insulin glargine or glimepiride, a sulphonylurea (SU) therapy [28]. Similarly, in two randomised parallel-group trials, a low incidence of hypoglycaemic events was associated with repaglinide treatment during Ramadan, occurring in similar …”

Section: Short-acting Insulin Secretagogues (Meglitinides)mentioning

confidence: 89%

See 1 more Smart Citation

Diabetes and Ramadan: Practical guidelines

Hassanein

Alarouj

Hamdy

et al. 2017

Diabetes Research and Clinical Practice

275

357

View full text Add to dashboard Cite

Section: Short-acting Insulin Secretagogues (Meglitinides)mentioning

confidence: 89%

“…Two smaller observational studies found insulin glargine to be safe to use during Ramadan, with no significant increases in hypoglycaemia when compared with non-fasting individuals or when compared with those taking OADs [26,28].…”

Section: Insulin Treatment For T2dmmentioning

confidence: 99%

Diabetes and Ramadan: Practical guidelines

Hassanein

Alarouj

Hamdy

et al. 2017

Diabetes Research and Clinical Practice

275

357

View full text Add to dashboard Cite

“…Al-Arouj et al [39] reported in their article that patients treated with metformin alone may safely fast because the possibility of hypoglycemia was minimal, and recommended that two thirds of the total daily dose be administered immediately before the sunset meal, while the other third be given before the predawn meal. However, glimepiride with its longer action may offer an advantage for diabetic fasters as reported by [40,41] , and didn't make a significant change in glucose and lipid parameters according to a recent Turkish study [42] . During Ramadan some of our subjects arbitrarily reduced their drug dosage or even stopped completely and developed hypoglycemia as a result.…”

Section: Food Consumptionmentioning

confidence: 99%

Ramadan Fasting Diet Entailed a Lipid Metabolic Disorder Among Type 2 Diabetic Obese Women

Khaled¹

2009

American Journal of Applied Sciences

View full text Add to dashboard Cite

Abstract:We designed this study to assess the effect of diet during Ramadan fasting on body weight and on serum lipid components in type 2 diabetic obese women. During Ramadan of 2005, 89 diabetic women receiving oral treatment (BMI = 33.20±3.01 kg m −2 ), aged 52 (±5 years), were selected. The study was carried out over 3 periods-, before (T1: pre-fasting), during (T2: fasting), and after (T3: post-fasting) Ramadan-in Sidi-bel-Abbes city. The daily food intake during the course of 3 days was recorded, and then weight, height, waist and hip circumferences, Body Mass Index (BMI) and Waist to Hip Ratio (WHR) were measured. Blood samples were analyzed for total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), apolipoprotein A1 (apoA-I), apolipoprotein B (apoB), triglycerides (TGs), fasting serum glucose (FSG), and glycated haemoglobin (HbA1c) and results were compared using Student's t-test. The dietary fat consumption increased during Ramadan, especially for the saturated one and as a result induced a major lipid unbalance, marked by a disorder observed in nearly all of the serum lipid components. There was a significant weight loss in diabetic women (-2.56 kg, p<0.05) during T2, correlated with a decrease in meal frequency (r 2 = 0.313, p<0.01). As well, the level of glucose decreased significantly during T2 (8.23±0.75 mmol L −1 ) compared to T1 (9.23±1.08 mmol L −1 ). Our study showed a significant weight loss during Ramadan period and an improvement of glucose homeostasis. However, the lipid metabolism was imbalanced and was strongly linked to the Ramadan diet and to the eating habits modification.

show abstract

“…No difference between the therapies was identified. 28 General advice is to use prandial regulators and short acting agents for the purpose of managing diabetes during Ramadan.…”

Section: Sulfonylurea and Prandial Regulatorsmentioning

confidence: 99%